GlassScriptPhysician profile
Thuy N Nguyen
NPI 1447362488
$7,967.74
in general payments reported to CMS, 2019-2025
38 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,787 · 2020: $1,489 · 2021: $1,791 · 2022: $933 · 2023: $1,244 · 2024: $590 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,225.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $661.13 | 2019-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $649.04 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $605.21 | 2019-2024 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $602.52 | 2019-2023 | Livalo, Seglentis |
| Amarin Pharma, INC. | $571.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $505.97 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $468.12 | 2021-2023 | |
| Astellas Pharma US INC | $334.55 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $331.97 | 2019-2021 | |
| Galderma Laboratories, L.P. | $264.95 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.94 | 2019-2023 | Xifaxan |
| Pfizer INC. | $153.57 | 2019-2024 | |
| Merz North America, INC. | $145.58 | 2023 | Xeomin |
| Janssen Pharmaceuticals, INC | $142.45 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $121.59 | 2019-2020 | |
| Radius Health, INC. | $120.78 | 2019 | |
| Leo Pharma INC. | $94.46 | 2025 | Adbry |
| Lilly USA, LLC | $93.67 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $88.03 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $83.00 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $70.63 | 2020-2021 | |
| Biofire Diagnostics, LLC | $40.00 | 2020 | |
| Eisai INC. | $39.70 | 2020-2021 | |
| Dexcom, INC. | $35.00 | 2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $28.62 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $24.91 | 2023 | Edarbi |
| Si-Bone, INC. | $23.97 | 2025 | |
| Ardelyx, INC. | $22.27 | 2024 | Ibsrela |
| Exact Sciences Corporation | $21.82 | 2024 | Cologuard Collection Kit |
| Alk-Abello, INC | $19.39 | 2019 | |
| Baxter Healthcare | $19.20 | 2024 | |
| Nestle Healthcare Nutrition INC. | $19.01 | 2021 | |
| Vivus LLC | $15.61 | 2023 | Qsymia |
| Takeda Pharmaceuticals U.S.A., INC. | $15.37 | 2019 | |
| Concordia Pharmaceuticals INC. | $15.10 | 2019 | |
| Ethicon US, LLC | $14.90 | 2021 | |
| Nabriva Therapeutics, Plc | $13.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.